TCG Crossover

What TCG Crossover does

TCG Crossover ("TCGX") is a science-driven healthcare investment firm founded in 2021 by Dr. Chen Yu after sixteen years as a Managing Partner at Vivo Capital. The firm manages a series of closed-end funds that deploy patient capital into biotech companies developing transformative medicines at any stage of their lifecycle. TCGX has raised three successive oversubscribed funds: the inaugural Fund I at $824M (April 2021), Fund II at $1B (January 2024), and Fund III at $1.3B (October 2025), bringing cumulative commitments to approximately $3.1 billion. Capital is deployed globally across North America, Europe, and China, with offices in Palo Alto (headquarters), New York, and San Francisco, and approximately 20-25 total employees.

The firm's core differentiator is its Science Network of eight Science Partners that includes Nobel-caliber scientists such as former HHMI President Robert Tjian, former Merck R&D head Roger Perlmutter (now CEO of Eikon Therapeutics), Lasker Award winner Charles Sawyers, and Pfizer board member Helen Hobbs. The investment team is led by three Managing Partners (Chen Yu, Cariad Chester, Giuliano Marostica) with operating, scientific, and investment banking backgrounds, supported by a venture formation-focused Venture Partner (Dandan Dong, ex-ArriVent Biopharma CBO) and Associates with credentials from Stanford, MIT, Harvard, NEA, Goldman Sachs, Evercore, and Foresite Capital. The Science Network functions as the firm's primary deal-sourcing channel and diligence engine, distinguishing TCGX from generalist crossover funds.

TCGX generates revenue through traditional fund management economics, charging management fees and earning performance carry on its closed-end fund vehicles. The firm does not sell products or services in the conventional sense; rather, it invests institutional LP capital into private and public biotech companies. Its portfolio of 25+ private companies spans modalities including ADCs, gene therapy, oral peptides, radiopharmaceuticals, cell therapy, and vaccines, with notable outcomes including pharma acquisitions by Roche (Carmot), AstraZeneca (Icosavax, Gracell), Eli Lilly (Versanis), GSK (RAPT Therapeutics), Sanofi (Vicebio), Novartis (Tourmaline Bio), and UCB (Candid Therapeutics), plus IPOs of CG Oncology and Structure Therapeutics.

Name

TCG Crossover

Legal name

TCG Crossover Management LLC

Website

https://tcgcrossover.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

TCG Crossover is a Palo Alto-based healthcare investment firm founded in 2021 that manages three oversubscribed closed-end funds totaling approximately $3.1 billion, deploying patient capital into biotech companies across all stages of development in North America, Europe, and China.

Ownership category

akta.pro rank

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. Fund Management: TCGX generates returns through management fees and performance carry from closed-end investment funds. They invest patient capital from institutional LPs without redemption pressure, allowing long-term commitment to portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

TCG Crossover (TCGX) is a science-driven healthcare investment firm that deploys patient capital from closed-end funds into innovative biotech companies developing transformative medicines. The firm invests at any stage of a company's lifecycle — from private financings to crossover and public offerings — across North America, Europe, and China. TCGX has raised three funds to date: TCG X Fund I ($824M, April 2021), TCGX Fund II ($1B, January 2024), and TCGX Fund III ($1.3B, October 2025).

Product overview

TCG Crossover ("TCGX") is an investment firm focused on innovative biotech companies. They do not offer a product in the traditional SaaS sense. Their offering consists of venture capital investment management, deploying capital from closed-end funds into biotech companies developing transformative medicines. They support both private and public companies across North America, Europe, and China, with Fund I, Fund II ($1B oversubscribed), and Fund III ($1.3B oversubscribed) as their investment vehicles. Their portfolio includes investments in companies such as ADARx Pharmaceuticals, Adcendo, Affinia Therapeutics, Aktis Oncology, Alkeus, Arbor Biotechnologies, Artios Pharma, Beacon Therapeutics, Candid Therapeutics, Carmot, CG Oncology, Damora, Eikon Therapeutics, Entrada Therapeutics, Obsidian Therapeutics, Korsana Biosciences, Pheon Therapeutics, Plexium, RayzeBio, ShouTi, Synthekine, Tourmaline Bio, Upstream Bio, Versanis Bio, and Vicebio.

Differentiator

Problem solved

Functional benefit

Products and services

• TCG X Fund I (Inaugural Fund) A closed-end investment fund that deploys patient capital into biotech companies at any stage of company lifecycle, targeting visionary entrepreneurs leveraging scientific breakthroughs.
• TCG Crossover Fund II Oversubscribed closed-end fund providing patient capital without redemption pressure to innovative biotech companies, enabling long-term commitment throughout drug development cycles.
• TCG Crossover Fund III Oversubscribed closed-end fund providing growth-stage and crossover capital to biotech companies, building on the strategy and track record of Funds I and II.

Quantifiable outcome

• TCG Crossover Fund III raised $1.3B (October 2025)
• +2 more outcomes

Named customers8 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core.

• Robert Tjian, PhDcoreStrategic or Co-development PartnerScience Partner at TCGX. Former President of Howard Hughes Medical Institute (2009-2016). Discovered first human transcription factors. Co-founder of Tularik. Serves as scientific advisor to Chan Zuckerberg Initiative and BioHub.
• Roger Perlmutter, MDcoreStrategic or Co-development PartnerScience Partner at TCGX. President, CEO and Chairman of Eikon Therapeutics. Former Executive VP at Merck & Co. and President of Merck Research Laboratories. Former EVP and head of R&D at Amgen. Fellow of American Academy of Arts and Sciences.
• Charles Sawyers, MDcoreStrategic or Co-development PartnerScience Partner at TCGX. Howard Hughes Medical Institute Investigator. 2009 Lasker-DeBakey Clinical Medical Research Award winner. Co-founder of Aragon Pharmaceuticals and Seragon Pharmaceuticals. Founder of ORIC Pharmaceuticals.
• Richard Scheller, PhDcoreStrategic or Co-development PartnerScience Partner at TCGX. Former Chief Scientific Officer at 23andMe. 2013 Albert Lasker Basic Medical Research Award winner. 2010 Kavli Prize in Neuroscience winner. Former EVP at Genentech.
• Vishva M. Dixit, MDcoreStrategic or Co-development PartnerScience Partner at TCGX. Vice President and Staff Scientist of Physiological Chemistry at Genentech. Member of National Academy of Sciences, National Academy of Medicine, American Academy of Arts and Sciences. Serves on boards of Gates Foundation and Howard Hughes Medical Institute.
• Huda Y. Zoghbi, MDcoreStrategic or Co-development PartnerScience Partner at TCGX. Investigator at Howard Hughes Medical Institute. Director of Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital. 2015 Breakthrough Prize in Life Sciences winner. Board member at Pfizer.
• Charles Zuker, PhDcoreStrategic or Co-development PartnerScience Partner at TCGX. Professor at Columbia University Medical Center and Investigator at Howard Hughes Medical Institute. Co-founder of Kallyope, Aurora Biosciences, and Senomyx.
• Helen Hobbs, PhDcoreStrategic or Co-development PartnerScience Partner at TCGX. Howard Hughes Medical Institute Investigator. 2015 Breakthrough Prize in Life Sciences winner. Discovered PCSK9 target leading to FDA-approved antibodies. Board of Directors at Pfizer, Inc.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Great Point Partners: Healthcare-dedicated investment manager with public and private strategies; comparable to TCGX in sector focus and notably the prior employer of TCGX Managing Partner Giuliano Marostica.
• Baker Bros. Advisors: Long-only biotech-focused adviser managing billions in AUM with deep scientific diligence and concentrated public/private biotech positions; highly comparable in mandate and crossover style to TCGX.
• RA Capital Management: Healthcare-focused crossover fund manager investing in public and private biotech companies at all stages; the closest direct competitor to TCGX in crossover investing strategy, scale, and biotech-focused mandate.
• Bain Capital Life Sciences: Healthcare-dedicated private equity and crossover franchise investing across biotech stages; directly comparable to TCGX and notably the prior employer of TCGX's Head of Trading (Brad Balter).
• The Column Group: Science-driven venture capital firm investing in early-stage biotech with world-class scientific founders; highly comparable in scientific-rigor approach and notably the primary affiliation of TCGX Science Partner Robert Tjian.
• OrbiMed: Healthcare-dedicated investment firm with multi-strategy funds spanning venture, growth, and public equities; directly comparable to TCGX as a healthcare specialist with similar stage-agnostic biotech mandate.
• Perceptive Advisors: Biotech-focused crossover fund manager with deep venture and PIPE activity; competes head-to-head with TCGX on crossover financings and late-stage biotech rounds.
• Vivo Capital: Healthcare-focused investment firm where TCGX founder Chen Yu spent 16 years as Managing Partner; virtually identical strategy of biotech PE/crossover investing and serves as the direct lineage precedent for TCGX.
• Foresite Capital Management: Healthcare and biotech-focused investment firm investing across private and public biotech; directly comparable to TCGX and notably the prior employer of TCGX Associate Suan Tuang.

Broad incumbents

• New Enterprise Associates (NEA): Large, multi-stage venture firm with a dedicated healthcare practice; broader in scope than TCGX but directly competes on biotech investments and notably the prior employer of TCGX Associate Michael Albert.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tcg-crossover

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments89 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TCG Crossover